Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease - PubMed (original) (raw)
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease
W J Strittmatter et al. Proc Natl Acad Sci U S A. 1993.
Abstract
Apolipoprotein E (apoE), a plasma apolipoprotein that plays a central role in lipoprotein metabolism, is localized in the senile plaques, congophilic angiopathy, and neurofibrillary tangles of Alzheimer disease. Late-onset familial and sporadic Alzheimer disease patients have an increased frequency of one of the three common apoE alleles, epsilon 4, suggesting apoE4 is associated with increased susceptibility to disease. To follow up on this suggestion, we compared the binding of synthetic amyloid beta (beta/A4) peptide to purified apoE4 and apoE3, the most common isoform. Both isoforms bound synthetic beta/A4 peptide, the primary constituent of the plaque and angiopathy, forming a complex that resisted dissociation by boiling in SDS. Oxygen-mediated complex formation was implicated because binding was increased in oxygenated buffer, reduced in nitrogen-purged buffer, and prevented by reduction with dithiothreitol or 2-mercaptoethanol. Binding of beta/A4 peptide was saturable at 10(-4) M peptide and required residues 12-28. Examination of apoE fragments revealed that residues 244-272 are critical for complex formation. Both oxidized apoE4 and apoE3 bound beta/A4 peptide; however, binding to apoE4 was observed in minutes, whereas binding to apoE3 required hours. In addition, apoE4 did not bind beta/A4 peptide at pH < 6.6, whereas apoE3 bound beta/A4 peptide from pH 7.6 to 4.6. Together these results indicate differences in the two isoforms in complexing with the beta/A4 peptide. Binding of beta/A4 peptide by oxidized apoE may determine the sequestration or targeting of either apoE or beta/A4 peptide, and isoform-specific differences in apoE binding or oxidation may be involved in the pathogenesis of the intra- and extracellular lesions of Alzheimer disease.
Similar articles
- Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S, Abraham CR, Zannis VI. Aleshkov S, et al. Biochemistry. 1997 Aug 26;36(34):10571-80. doi: 10.1021/bi9626362. Biochemistry. 1997. PMID: 9265639 - [Lipoproteins in clinical laboratory medicine].
Kuriyama M. Kuriyama M. Rinsho Byori. 1998 Dec;46(12):1219-25. Rinsho Byori. 1998. PMID: 9916507 Review. Japanese. - Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma.
Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. Yang DS, et al. J Neurochem. 1997 Feb;68(2):721-5. doi: 10.1046/j.1471-4159.1997.68020721.x. J Neurochem. 1997. PMID: 9003062 - Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L. Buttini M, et al. J Neurosci. 2002 Dec 15;22(24):10539-48. doi: 10.1523/JNEUROSCI.22-24-10539.2002. J Neurosci. 2002. PMID: 12486146 Free PMC article. - [Apolipoprotein E4 and late-onset Alzheimer's disease].
Tamaoka A. Tamaoka A. Nihon Rinsho. 1994 Dec;52(12):3257-65. Nihon Rinsho. 1994. PMID: 7853720 Review. Japanese.
Cited by
- The membrane axis of Alzheimer's nanomedicine.
Li Y, Tang H, Andrikopoulos N, Javed I, Cecchetto L, Nandakumar A, Kakinen A, Davis TP, Ding F, Ke PC. Li Y, et al. Adv Nanobiomed Res. 2021 Jan;1(1):2000040. doi: 10.1002/anbr.202000040. Epub 2020 Nov 26. Adv Nanobiomed Res. 2021. PMID: 33748816 Free PMC article. - Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.
Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A, Gasser T, Berg D. Maetzler W, et al. PLoS One. 2012;7(10):e48042. doi: 10.1371/journal.pone.0048042. Epub 2012 Oct 25. PLoS One. 2012. PMID: 23133543 Free PMC article. - Genetics of Alzheimer's disease in Caribbean Hispanic and African American populations.
Reitz C, Mayeux R. Reitz C, et al. Biol Psychiatry. 2014 Apr 1;75(7):534-41. doi: 10.1016/j.biopsych.2013.06.003. Epub 2013 Jul 25. Biol Psychiatry. 2014. PMID: 23890735 Free PMC article. Review. - Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.
Reitz C, Mayeux R. Reitz C, et al. J Alzheimers Dis. 2010;19(1):229-51. doi: 10.3233/JAD-2010-1255. J Alzheimers Dis. 2010. PMID: 20061642 Free PMC article. Review. - Genetic variation at a single locus and age of onset for Alzheimer's disease.
Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Lutz MW, et al. Alzheimers Dement. 2010 Mar;6(2):125-31. doi: 10.1016/j.jalz.2010.01.011. Alzheimers Dement. 2010. PMID: 20298972 Free PMC article.
References
- J Biol Chem. 1978 Sep 10;253(17):6281-8 - PubMed
- Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10540-3 - PubMed
- J Biol Chem. 1981 Apr 10;256(7):3348-53 - PubMed
- J Clin Endocrinol Metab. 1983 Nov;57(5):969-74 - PubMed
- J Biol Chem. 1983 Oct 25;258(20):12341-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous